Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma

Sridhar Mani, David Sciortino, Brian Samuels, Rose Arrietta, Richard L. Schilsky, Everett E. Vokes, Steven Benner

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Precis: UFT 300 mg/m2/day and leucovorin 90 mg/day could be administered safely to patients with advanced biliary cancer with good performance status; however, this combination and schedule of 28-day administration has no activity in this disease. Purpose: To determine the activity and evaluate the toxicity of uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) plus oral calcium leucovorin in the treatment of patients with advanced biliary (gallbladder and bile duct) carcinoma. Patients and methods: Thirteen patients with advanced measurable biliary carcinoma were enrolled onto the trial. All patients had a Karnofsky performance status ≥ 60%, platelet count ≥ 75,000/μL, total bilirubin ≤ 2.0 x institutional upper limit of normal but otherwise normal liver and kidney function profile and bidimensionally measurable disease by CT scan or ultrasound examination. None of these patients previously received cytotoxic chemotherapy or radiation therapy for advanced disease. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided daily doses every 8 hours for 28 days repeated every 35 days. Objective tumor response, the primary endpoint of this trial, was evaluated after two courses of therapy. Other endpoints included toxicity, time to progression, and overall survival. Results: All patients were evaluable for response and toxicity. No complete or partial responses were observed in this trial. Four patients had stable disease lasting 17, 30, 33, and 35 weeks, respectively. The median (range) time to progression and survival were 9 (1-35) and 28 (1-61) weeks, respectively. Treatment-related toxicity was mild with severe (grade 3 or 4) diarrhea seen in 2 (15%). Grade 3-4 hyperbilirubinemia (31%) and nausea/vomiting (31%) were observed and likely related to the underlying disease. Grade 1 and 2 toxic effects included mainly anorexia and fatigue. Conclusion: UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days repeated every 35 days is ineffective in the treatment of advanced biliary carcinoma.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalInvestigational New Drugs
Volume17
Issue number1
DOIs
StatePublished - Oct 6 1999

    Fingerprint

Keywords

  • Bile duct carcinoma
  • Biliary
  • Cholangiocarcinoma
  • Ftorafur
  • Leucovorin
  • Uracil

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Mani, S., Sciortino, D., Samuels, B., Arrietta, R., Schilsky, R. L., Vokes, E. E., & Benner, S. (1999). Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Investigational New Drugs, 17(1), 97-101. https://doi.org/10.1023/A:1006268018519